Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were
treated with intravenous ganciclovir. Twenty-one patients had received transplants—15 …

The efficacy and safety of ganciclovir were evaluated for the treatment of 39 life-threatening
or sight-threatening cytomegalovirus (CMV) infections in recipients of bone marrow …

Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CMV)
infections in 22 heart and heart-lung transplant recipients at six medical centers was …

The clinical and virologic efficacy of ganciclovir (9-[1, 3-dihydroxy-2-propoxymethyl]
guanine) in the treatment of severe CMV infections in solid organ transplant recipients was …

CYTOMEGALOVIRUS (CMV) infections are a major cause of morbidity and mortality among
immunocompromised patients, especially recipients of bone marrow and solid-organ …

Ganciclovir is a congener of acyclovir with in vitro activity against cytomegalovirus. Ninety-
seven patients with the acquired immune deficiency syndrome (AIDS) and a serious …

Abstract Treatment of cytomegalovirus (CMV) disease met with limited success until the
development of ganciclovir. Favorable clinical responses to ganciclovir have been reported …

A total of 314 immunocompromised patients with serious cytomegalovirus (CMV) infection
treated with ganciclovir administered intravenously were studied. Rates of favorable clinical …

Synopsis The antiviral nucleoside analogue ganciclovir has demonstrated in vitro activity
against human cytomegalovirus and effectively treats infection caused by this organism in …

MATERIALS AND METHODS Seventeen patients–12 who had received orthotopic liver
transplants and 5 who had orthotopic kidney transplants at our institution–received …